Brokers Set Expectations for Pyxis Oncology FY2030 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities research analysts at HC Wainwright raised their FY2030 earnings per share estimates for Pyxis Oncology in a report issued on Thursday, September 10th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.79 for the year, up from their previous estimate of $0.76. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.21) per share.

A number of other equities analysts have also commented on PYXS. Wedbush raised their target price on shares of Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday. Wells Fargo & Company boosted their price target on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Finally, Leerink Partners reduced their price objective on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.75.

Pyxis Oncology Price Performance

Shares of PYXS opened at $3.43 on Monday. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55. The company has a 50-day moving average of $3.05 and a 200 day moving average of $2.26. The firm has a market capitalization of $286.10 million, a price-to-earnings ratio of -2.43 and a beta of 1.34.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05).

Institutional Trading of Pyxis Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in PYXS. Atle Fund Management AB acquired a new position in shares of Pyxis Oncology during the 4th quarter worth approximately $710,000. 683 Capital Management LLC grew its stake in Pyxis Oncology by 69.9% in the 4th quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after acquiring an additional 366,910 shares during the period. Renaissance Technologies LLC grew its stake in Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after acquiring an additional 160,300 shares during the period. Finally, J. Derek Lewis & Associates Inc. purchased a new stake in Pyxis Oncology in the 4th quarter worth $61,000. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing therapies for patients with cancer. The company’s approach is centered on creating antibody-based medicines designed to selectively target tumor cells or the tumor microenvironment while delivering therapeutic activity intended to improve cancer treatment outcomes.

Pyxis Oncology’s pipeline has included PYX-201, an antibody-drug conjugate designed to target extra-domain B fibronectin, a protein associated with the tumor microenvironment, and PYX-106, an investigational antibody targeting SIGLEC-15, an immune-regulatory protein expressed in several cancers.